Bayer extends clinical trial program for Kerendia™ (finerenone) with observational study in patients with chronic kidney disease and type 2 diabetes to learn more about the use of finerenone in real world settings.

Diegem, September 8 - 2022 – Bayer announced that the first patient was included in the non-interventional study FINE-REAL, which will explore the use of Kerendia™ (finerenone) as a treatment for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The main purpose of the study is to learn more about treatment patterns in patients with CKD and T2D who will start finerenone as decided and prescribed by their doctor as part of their routine medical care, as well as understand the reasons for prescription. 1 The FINE-REAL study will provide insights about finerenone in real-world...